In a phase II study, 42 patients with advanced soft-tissue sarcoma were treated with ifosfamide by 24-h infusion and mesna by 4-h IV bolus, repeated every 3 weeks. Ten patients received ifosfamide 5.0 g/m2, 20 had the dosage increased to 8.0 g/m2, and 12 received 8.0 g/m2 from the outset. Mesna was
Treatment of advanced soft tissue and osteogenic sarcomas with continuous infusion of ifosfamide and mesna
β Scribed by H. O. Klein; P. Dias Wickramanayake; C. Coerper; E. Christian
- Publisher
- Springer
- Year
- 1986
- Tongue
- English
- Weight
- 44 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas. Forty consecutive patients with a median age of 35.5 years were treated. Ifosfamide was administered at a dose of 2.5 g/m 2 /day as 72-hour con
## BACKGROUND. Successful chemotherapy for patients with soft tissue sarcoma (STS) has been limited by a lack of active drugs. The most effective single agents are doxorubicin, dacarbazine, and, more recently, ifosfamide. Previously the most widely used combination has been CYVADIC (cyclophosphami
4 13Β°C.
## Background: Standard therapy for pediatric nonrhabdomyosarcoma soft tissue sarcomas (pnrsts) consists of surgical resection with or without radiotherapy. the role of chemotherapy in the treatment of these tumors has not yet been defined. we investigated the efficacy and toxicity of an ifosfamide